Company Overview and News

 
Sterlite Power’s infra investment trust eyeing third-party transmission assets

4h thehindubusinessline
India Grid Trust (IndiGrid), the infrastructure investment trust (InvIT) promoted by one of the largest players in India’s power transmission sector, Sterlite Power, is scouting for power transmission assets available in the market for sale as it aims to grow its portfolio, Harsh Shah, CEO of India Grid Trust told BusinessLine.
532627 JPPOWER

 
JSW Energy mulls expanding hydro portfolio

2018-10-11 thehindubusinessline
India currently has 38 under construction Hydro Electric Projects. Image for representational purpose. - The Hindu
500228 532627 JPPOWER JSWSTEEL JSWENERGY 533148

 
These 10 stocks were hammered in 2018, do you own any?

2018-10-09 moneycontrol
Since the turn of the year, the Indian benchmark indices have not witnessed significant erosion in value, but large cap stocks have been hit badly. Here are some of the worst performing stocks of the year, to date. The list has been compiled by Moneycontrol by sifting through the Ace Equity database. The comparative analysis undertaken here includes only the stocks of companies with market capitalisation above Rs 5,000 crore.
SUZLON SRI SREINFRA JIPKY 532617 532712 RCOM 532461 SUEL YESBANK SIFLY 523756 532627 JETAIRWAYS JPASSOCIAT 532648 SRIA YYBKY 532667 532532 PNJZY JPPOWER PNB 534809 PCJEWELLER

 
ICICI Bank moves NCLT against Jaiprakash Power

2018-10-04 financialexpress
ICICI Bank has initiated insolvency proceedings against Jaiprakash Power Ventures, filing an application under Section 7 of the Insolvency and Bankruptcy Code (IBC) with the Ahmedabad bench of the National Company Law Tribunal (NCLT). The company’s total debt stood at Rs 20,143 crore at the end of March 2018. In a notice to the exchanges, Jaiprakash Power said on Thursday, “This is to inform you that as per the notice received by the Company, ICICI Bank has filed an application under Section 7 of the Insolvency and Bankruptcy Code, 2016, for initiating Corporate Insolvency Resolution Process (CIRP) for the company with the National Company Law Tribunal (NCLT), Ahmedabad.
532532 ICICIBANK JIPKY 532174 IBN 532627 JPPOWER JPASSOCIAT

 
Jaiprakash Power Ventures Limited - Corporate Insolvency Resolution Process

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

 
Jaiprakash Power Ventures Limited - Shareholders meeting

2018-09-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

 
Jaiprakash Power Ventures Limited - Shareholders meeting

2018-09-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

 
India banks to plan resolving $19 billion power sector debt on Thursday

2018-09-19 livemint
Mumbai/New Delhi: Lenders to India’s power industry are scheduled to meet on Thursday to discuss ways to resolve ₹1.4 trillion ($19.2 billion) of stressed assets that’s hobbling the sector, people with knowledge of the matter said.
PFC PWQFY 532627 JPPOWER 532955 RECLTD 532810 SBAZ

 
Jaiprakash Power Ventures Limited - AGM/Book Closure

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

 
Union Bank of India expects Rs 2,000 crore recovery from resolution of stressed power projects

2018-09-05 moneycontrol
State-owned Union Bank of India hopes to recover Rs 2,000 crore from the resolution of three stressed thermal power units as there has been interest from other operators in these projects.
UBNC 532627 JPPOWER

 
Check out the top 10 stocks which moved the most last week

2018-09-02 moneycontrol
Equities did not have the best of their starts to a new series, with the Nifty ending the first day of September series below 11,700-mark. However, bulls did manage to battle it out well with the bears as the market was off its low points.
500219 ABBOTINDIA 570004 RELEY RIFS 539254 RELFF 532627 JISLJALEQS TCHQY 532778 532755 TECHM 500390 RELINFRA JISLDVREQS RIFA JPPOWER 500488 LITL ADANITRANS

 
JP Power Ventures: Board to settle lenders

2018-08-31 thehindubusinessline
The board of Jaiprakash Power Ventures on Friday approved a proposal to alter its MoA to increase its authorised share capital to ₹20,050 crore from ₹10,050 crore, mainly to convert the debt of lenders into equity (by cumulative compulsory convertible preference shares up to ₹4,000 crore). The board also approved an issue of 35.20 crore shares on preferential basis to unsecured creditors. The lenders include ICICI Bank, IDBI Bank, PNB, Central Bank, SBI, UBI and Canara Bank.
ICICIBANK 500116 532483 532174 IBN IDBI 532627 JPPOWER CANBK CNRYY

 
JPVL board approves hike in authorised capital, conversion of Rs 4,000 crore debt into equity

2018-08-31 moneycontrol
Jaiprakash Power Ventures today said its board has approved the proposal to alter its memorandum of association to increase authorised share capital of the company to Rs 20,050 crore from Rs 10,050 crore, mainly to convert debt of lender into equity.
IOB UDBKL IDBI UBLS 532418 532388 SYNDIBANK 532121 532461 532483 UBLA 532480 SBAZ UBNC 500116 IBN 532627 ALBK CNRYY 532179 ICICIBANK 532276 PNJZY CRPKY 532174 JPPOWER PNB CORPBANK CANBK DENABANK ANDHRABANK

 
Jaiprakash Power Ventures Limited - Outcome of Board Meeting

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

 
Deals Buzz: NCLT approves Vodafone-Idea merger

2018-08-31 livemint
The National Company Law Tribunal gave its nod to the merger of Vodafone and Idea, which will create India’s largest telecom company, displacing Bharti Airtel from the top spot, The Economic Times reported. The new entity will have 440 million subscribers, a 34.7% revenue market share (RMS), revenue of more than Rs 60,000 crore and combined debt of over Rs 1.15 lakh crore. Mint reported on July 11 that telecom minister Manoj Sinha said the merger is approved with only formalities remaining.
532454 TATAPOWER 532627 TPCL JPPOWER 500400 BHRQY BHARTIARTL JSWENERGY 533148

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...